Q3 Earnings Estimate for BPMC Issued By Wedbush
Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) – Equities research analysts at Wedbush issued their Q3 2026 EPS estimates for Blueprint Medicines in a note issued to investors on Wednesday, April 16th. Wedbush analyst D. Nierengarten expects that the biotechnology company will post earnings of $0.17 per share for the quarter. Wedbush has a “Outperform” […]
More Stories
NewEdge Advisors LLC Sells 410 Shares of First Community Bankshares, Inc. (NASDAQ:FCBC)
NewEdge Advisors LLC decreased its position in First Community Bankshares, Inc. (NASDAQ:FCBC – Free Report) by 21.3% during the 4th...
Albertsons Companies, Inc. (NYSE:ACI) Stock Position Decreased by NewEdge Advisors LLC
NewEdge Advisors LLC lowered its holdings in Albertsons Companies, Inc. (NYSE:ACI – Free Report) by 20.3% during the fourth quarter,...
Marshall Wace LLP Has $463,000 Stock Holdings in ProAssurance Co. (NYSE:PRA)
Marshall Wace LLP increased its position in ProAssurance Co. (NYSE:PRA – Free Report) by 21.0% in the 4th quarter, according...
Marshall Wace LLP Purchases New Position in Woodward, Inc. (NASDAQ:WWD)
Marshall Wace LLP acquired a new position in shares of Woodward, Inc. (NASDAQ:WWD – Free Report) in the fourth quarter,...
Marshall Wace LLP Sells 27,500 Shares of Organon & Co. (NYSE:OGN)
Marshall Wace LLP lowered its holdings in shares of Organon & Co. (NYSE:OGN – Free Report) by 48.7% in the...
Marshall Wace LLP Purchases Shares of 14,414 Rayonier Inc. (NYSE:RYN)
Marshall Wace LLP acquired a new position in Rayonier Inc. (NYSE:RYN – Free Report) during the 4th quarter, according to...